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Abstract: In addition to exerting actions via mineralocorticoid and 
glucocorticoid receptors, corticosteroids also act by inhibiting uptake2, a high-
capacity monoamine transport system originally described in peripheral 
tissues. Recent studies have demonstrated that uptake2 transporters are 
expressed in the brain and play roles in monoamine clearance, suggesting 
that they mediate some corticosteroid effects on physiological and behavioral 
processes. However, the sensitivity of brain uptake2 to many natural and 
synthetic corticosteroids has not been characterized. Cultured rat cerebellar 
granule neurons (CGNs) were previously shown to exhibit corticosterone-
sensitive accumulation of the uptake2 substrate1-methyl-4-phenylpyridinium 
(MPP+). We examined the expression of uptake1 and uptake2 transporters in 
CGNs, and tested the effects of a variety of natural and synthetic 
corticosteroids on accumulation of [3H]-MPP+ by these cells. Cultured rat 
CGNs expressed mRNA for three uptake2-like transporters: organic cation 
transporters 1 and 3, and the plasma membrane monoamine transporter. 
They did not express mRNA for the dopamine or norepinephrine transporters, 
and expressed very little mRNA for the serotonin reuptake transporter. 
Accumulation of [3H]-MPP+ by CGNs was dose-dependently inhibited by 
corticosterone and decynium-22, known inhibitors of uptake2. Accumulation of 
MPP+ was also dose-dependently inhibited, with varying efficacies, by 
aldosterone, 11-deoxycorticosterone, cortisol, and cortisone, and by the 
synthetic glucocorticoids betamethasone, dexamethasone and prednisolone, 
and the glucocorticoid receptor antagonist RU38486. These studies 
demonstrate that uptake2 in the CNS is inhibited by a variety 
of natural and synthetic corticosteroids, and suggest that inhibition of 
uptake2-mediated monoamine clearance may underlie some behavioral and 
physiological effects of these hormones. 
 





Natural and synthetic corticosteroids are powerful modulators of 
neuronal physiology and behavior. By actions at a variety of cellular 
targets, they initiate both rapid and delayed effects on central nervous 
system (CNS) function. Recent studies suggest that, in addition to 
exerting actions via the mineralocorticoid and glucocorticoid receptors 
(MR and GR), corticosteroids also act by inhibiting monoamine 
clearance mediated by uptake2, a high-capacity, low-affinity transport 
system for norepinephrine, epinephrine, dopamine, histamine and 
serotonin [1-4]. In contrast to uptake1, which is mediated by a 
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combination of the specific transporters for norepinephrine (NET), 
dopamine (DAT), and serotonin (SERT), uptake2 is a higher-capacity 
but lower affinity transport system, and is acutely inhibited by 
corticosterone and other steroids [5, 6]. Inhibition of uptake2 in 
cardiac or smooth muscle tissue by acute bath application of 
corticosteroids enhances the contractile effects of exogenously applied 
epinephrine, norepinephrine, serotonin and histamine [7-12]. Recent 
studies have identified a small group of transporters that mediate 
uptake2-like transport and have demonstrated their expression in the 
brain [3, 4, 13-15]. Thus, uptake2 is a mechanism by which 
corticosteroids may act to enhance the actions of monoamines in the 
CNS as well as in peripheral targets. 
 
Uptake2 activity has been attributed to a group of broadly-
specific organic cation transporters. These include the organic cation 
transporter (OCT) family: OCTs 1, 2 and 3, and the plasma membrane 
monoamine transporter (PMAT). Because OCT3 is the most sensitive of 
these transporters to inhibition by corticosterone, it has been 
described as the most important uptake2 transporter[16-18]. However, 
all of the above transporters have uptake2-like characteristics. All are 
broadly-specific organic cation transporters, capable of transporting, 
with varying efficiencies, norepinephrine, epinephrine, serotonin, 
dopamine and histamine, as well as the cationic neurotoxin 1-methyl-
4-phenylpyridinium (MPP+) [13, 16, 19, 20]. All are sensitive to 
inhibition by corticosterone, though their sensitivities differ widely [3, 
13, 17, 18, 21, 22], and all are inhibited by the pseudoisocyanine 
compound 1, 1’-diethyl-2, 2’-cyanine iodide 
(decynium-22) [13, 23]. 
 
All of the uptake2 transporters are expressed, at varying levels 
and with distinct distributions, in rodent and human brain [3, 4, 13-
15], and recent studies suggest that they play important roles in 
monoamine clearance. Pharmacological inhibition of uptake2 by direct 
application of decynium-22 decreases the rate of serotonin clearance 
in mouse hippocampus [1], and treatment of rats with the OCT3 
inhibitor normetanephrine potentiates venlafaxine-induced increases in 
extracellular norepinephrine concentrations in rat prefrontal cortex 
[24]. Extracellular concentrations of dopamine are elevated in the 
striatum of OCT3 knockout mice [25]. These studies demonstrate that 
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uptake2 transporters play important roles in regulating extracellular 
concentrations of monoamines in the rodent brain. 
 
Each of the identified uptake2-like transporters is inhibited by 
corticosterone, though they differ in their sensitivity to this 
corticosteroid. OCT3 is the most sensitive (IC50 = 0.04 – 0.2 μM), 
followed by OCT2 (IC50 = 4 μM), OCT1 (IC50 = 150 μM) and PMAT (Ki 
= 450 μM) [3, 13, 17, 18, 21, 22]. Studies in peripheral tissues 
suggest that uptake2-mediated transport is also inhibited by a variety 
of natural and synthetic corticosteroids. In vascular smooth muscle, 
the mineralocorticoids aldosterone and 11-deoxycorticosterone 
enhance the contractile effects of epinephrine [26, 27], and OCT3-
mediated norepinephrine clearance in bronchial smooth muscle is 
inhibited by the synthetic corticosteroids budesonide, 
methylprednisolone, and fluticasone [28]. These studies suggest that 
uptake2 inhibition may play an important role in mediating the effects 
of both natural and synthetic corticosteroids on neuronal physiology 
and behavior. 
 
Given the powerful behavioral effects attributed to a wide 
variety of both natural and synthetic corticosteroids, it is important to 
understand the potential contribution of uptake2 inhibition to their 
actions in the CNS. However, the structure activity relationships 
among the natural and synthetic corticosteroids for inhibition of 
uptake2 in neurons have not been determined. We recently 
demonstrated that rat cerebellar granule neurons (CGNs) in culture 
accumulate [3H]-MPP+ in a corticosterone-sensitive manner, and that 
they express the uptake2 transporter OCT3, but not the uptake1 
transporter DAT [29]. In the present studies, we fully characterized 
the expression of uptake1 and uptake2 transporters in CGNs, and 
examined the sensitivity of uptake2-mediated accumulation of [3H]-
MPP+ to various natural and synthetic corticosteroid hormones. This 
information is important for a full understanding of the mechanisms by 
which corticosteroids influence CNS function. 
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All steroids were purchased from Steraloids (Newport, RI). 
Timed pregnant female Sprague-Dawley rats were purchased from 
Harlan (Madison, WI). 1-[3H]-Methyl-4-phenylpyridinium ([3H]- 
MPP+) (specific activity of 86.4 Ci/mol) was purchased from Perkin 
Elmer (Waltham, MA). Primers for RT-PCR were synthesized by 
Invitrogen (Carlsbad, CA). 
 
2.2. Culture of cerebellar granule neurons 
 
CGNs were prepared from 6-8-day-old rat pups of either sex as 
described previously [30] except that cerebellae were incubated in 40 
rather than 20 U/mL of papain. Cells were plated onto 6-well culture 
plates (2 ml, 1x106 cells/mL) and were maintained in basal minimal 
Eagle’s media (BME; Invitrogen) supplemented with 10% heat-
inactivated fetal bovine serum, 25 mM KCl, 5 mM glutamine, and 0.01 
mg/ml ampicillin. After 24 h, cytosine arabinoside (10 μM) was added 
to the cultures to inhibit glial proliferation. After 5 days in culture, 600 
μl of the media was removed and replaced with BME supplemented as 
above, except that B-27 (Invitrogen) was substituted for fetal bovine 
serum. 
 
2.3. [3H]-MPP+ uptake assay 
 
Uptake experiments were carried out at room temperature on 
CGNs that had been in culture for 6-8 days. Cells were washed and 
pre-incubated in 1.8 mL transport buffer (25 mM Tris Base, pH 8.5, 
280 mM mannitol, 5.4 mM KCL, 1.8 mM CaCl2, 0.8 mM MgSO4 and 5 
mM glucose). To test the effects of putative uptake2 inhibitors on MPP+ 
accumulation, CGNs were incubated in the presence of vehicle or 
increasing concentrations of inhibitors for 5 minutes before the 
addition of 20 nM [3H]-MPP+. Uptake was terminated after two minutes 
by aspiration of transport buffer, followed by two washes with 1mL 
icecold transport buffer. CGNs were lysed by scraping in 500 μl water. 
Radioactivity in the cell lysate was determined by liquid scintillation 
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spectroscopy. Uptake experiments were repeated at least three times, 
except where noted. The effects of the following inhibitors were 
tested: 11-dehydrocorticosterone (10 nM – 5.0 μM); 11-
deoxycorticosterone (10 nM- 1 μM); aldosterone (10 nM – 1 μM); 
betamethasone (10 nM – 1 μM); corticosterone (10 nM – 5 μM); 
cortisol (10 nM – 10 μM); cortisone (10 nM – 5 μM); decynium-22 
(0.01 nM – 0.1 μM); dexamethasone (0.1 nM – 1 μM); prednisolone 
(10 nM – 5 μM); RU38486 (10 nM – 5 μM). 
 
2.4. Reverse transcriptase-PCR 
 
After 7 days in culture, CGNs were washed twice with transport 
buffer and total RNA was isolated using 1 mL TRIzol Reagent 
(Invitrogen) per well according to the manufacturer's protocol. One 
microgram of the resulting total RNA was reverse transcribed in the 
presence and absence SuperScript™II Reverse Transcriptase 
(Invitrogen) using oligo(dT)20 primers. Two microliters of the resulting 
cDNA were used as a template for PCR reactions using GoTaq Green 
Master Mix (Promega, Madison, WI) and gene specific primers 
(Invitrogen) at 1 μM. Sequences for gene-specific primers and the 
corresponding PCR cycling parameters are shown in Table 1. 
 
((TABLE 1 here)) 
 
2.5. Data Analysis 
 
Results of uptake assays are expressed as means ± SEM from 
independent replicates. Uptake data were analyzed using GraphPad 
Prism version 5.03 (GraphPad Software, San Diego, CA). Transport 
data were analyzed by fitting untransformed data to appropriate 
equations using iterative, least-squares curve-fitting techniques. IC50 
values for inhibitors were determined by fitting the pooled data from 
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((FIGURE 1 here)) 
 
3.1. Expression of transporter mRNA in CGNs 
 
RT-PCR was used to determine the expression of mRNA for 
uptake1 (DAT, NET and SERT) and uptake2 (OCT1, OCT2, OCT3 and 
PMAT) transporters in CGNs. All primer pairs were tested for their 
ability to amplify the target genes from cDNAs obtained from tissues 
known to express each of the transporters. All primer pairs were able 
to amplify products of the expected size in cDNA from positive control 
tissue: midbrain for OCT3, OCT2, PMAT, DAT, NET and SERT; and 
kidney for OCT1(a and b) and OCT2; data not shown). As shown in 
Figure 1, mRNAs for OCT1, OCT3, and PMAT were clearly detected in 
CGNs, while mRNA for SERT was detected at very low levels, and 
mRNAs for OCT2, DAT, and NET were not detected. Because the 
results of the current OCT1 RT-PCR contradicted our previous results 
[29], we repeated the OCT1 PCR using either the primer pair that we 
used in the earlier publication (OCT1b), or the new primer pair 
(OCT1a). Using the OCT1a primer pair, we detected OCT1 mRNA in 
CGNs, as well as in forebrain, liver, kidney and lung. Using the OCT1b 
primer pair, we failed to detect OCT1 mRNA in CGNs or in rat 
forebrain, but did detect OCT1 mRNA in kidney, liver and lung tissue 
(data not shown). 
 
((FIGURE 2 here)) 
 
((FIGURE 3 here)) 
 
3.2. [3H]-MPP+ uptake assays 
 
Previous studies demonstrated saturable accumulation of [3H]-
MPP+ by cultured CGNs, and presented evidence that this accumulation 
was mediated by OCT3 (Shang et al, 2003). We tested the sensitivity 
of CGN accumulation of [3H]-MPP+ to the potent uptake2 inhibitor 
decynium-22, and to a variety of natural and synthetic corticosteroids. 
Uptake of [3H]-MPP+ was inhibited by both decynium-22 and 
corticosterone in a dose dependent manner, with decynium-22 
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inhibiting a larger fraction of MPP+ accumulation than did 
corticosterone (Figure 2, Table 2). Accumulation of [3H]-MPP+ was also 
partially inhibited by other naturally occurring corticosteroids and their 
metabolites, including aldosterone, cortisol, 11-deoxycorticosterone 
(11-DOC), and cortisone (Figure 3-4, Table 2). These steroids inhibited 
[3H]-MPP+ uptake with efficacies similar to that of corticosterone 
(Table 2). 11-Dehydrocorticosterone had only a slight inhibitory effect 
on [3H]-MPP+ uptake (Figure 4, Table 2). Synthetic corticosteroids 
inhibited [3H]-MPP+ uptake with varying efficacies. Betamethasone 
inhibited uptake with an efficacy similar to that of corticosterone, while 
dexamethasone and prednisolone were less effective (Figure 5, Table 
2). The glucocorticoid receptor antagonist RU38486 inhibited [3H]-
MPP+ uptake, but was less effective than corticosterone (Figure 5,Table 
2). Decynium-22 inhibited a larger fraction of uptake than did any of 
the steroids examined (Figure 2, Table 2). 
 




This study is the most detailed characterization of the 
corticosteroid sensitivity of uptake2-mediated transport, and the first in 
CNS cells. The data from expression and functional studies indicate 
that uptake2 is the primary monoamine transport system in CGNs, and 
that, as in peripheral tissue, uptake2 activity in the CNS is broadly 
sensitive to inhibition by both natural and synthetic corticosteroid 
hormones. These data are consistent with the hypothesis that natural 
and synthetic corticosteroids exert modulatory actions in the CNS via 
inhibition of uptake2 -mediated clearance of monoamines, and that 
inhibition of uptake2 -mediated monoamine clearance may underlie 
some of the effects of these hormones on neuronal physiology and 
behavior. 
 
((FIGURE 4 here)) 
 
The data from RT-PCR studies indicate that [3H]-MPP+ 
accumulation by CGNs is mediated primarily by three uptake2 
transporters: OCT1, OCT3 and PMAT. These data are consistent with 
previous studies demonstrating expression of OCT3, OCT1 and PMAT 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Physiology & Behavior, Vol. 104, No. 2 (August 2011): pg. 306-311. DOI. This article is © Elsevier and permission has been 
granted for this version to appear in e-Publications@Marquette. Elsevier does not grant permission for this article to be 
further copied/distributed or hosted elsewhere without the express permission from Elsevier. 
9 
 
protein or mRNA expression in the cerebellar granule layer [4, 14, 31]. 
However, our detection of OCT1 mRNA expression in CGNs is not 
consistent with our previous report that OCT1 mRNA is not expressed 
in these cells [29]. This discrepancy may be due to the use of different 
primer sets in the two studies. In the present study, we used a primer 
set (OCT1a) that targets the 3’ end of the OCT1 cDNA, whereas in the 
previous study, we used a primer set (OCT1b) that targets a region in 
the middle of the OCT1 cDNA. Both primer sets detected OCT1 mRNA 
in cDNA from kidney, raising the possibility that kidney and brain OCT1 
mRNAs represent alternatively spliced forms of the gene, as has been 
reported for human OCT1 [32]. To address this discrepancy, we 
performed parallel PCR using each of the OCT1 primer pairs to amplify 
product from CGN and kidney cDNAs. Using the OCT1b primers (from 
our earlier publication), we again detected OCT1 mRNA in kidney, but 
not in CGN cDNA. Using the OCT1a primers, we detected OCT1 mRNA 
in both kidney and CGN. These results suggest that the OCT1 mRNA 
we detected in CGNs represents an alternatively spliced form of the 
gene. Further studies are required to test this hypothesis. 
 
The data from RT-PCR studies further demonstrate that CGNs do 
not express DAT and NET, and that they express only very low levels 
of SERT. These results are consistent with previous studies examining 
DAT and SERT mRNA expression in CGNs [29, 33]. Our data on the 
expression of these uptake1 transporters seem to contradict previous 
studies demonstrating the expression of DAT, NET and SERT in the 
cerebellar granule layer. However, these studies measured radioligand 
binding in intact brain sections, or uptake of substrates by acutely-
prepared synaptosomes [34-38]. Data obtained using these techniques 
likely reflect transporters expressed on monoaminergic terminals in 
the cerebellar granule layer [39-41], rather than specifically in CGNs. 
Our data reflect transporter expression almost exclusively in CGNs. 
 
((FIGURE 5 here)) 
 
Our functional studies are also consistent with a primary role of 
uptake2 in CGN transport. Two well-characterized uptake2 inhibitors, 
decynium-22 and corticosterone, each inhibited substantial fractions of 
MPP+ uptake in the present studies. All of the transporters we detected 
in CGNs are inhibited by decynium-22, though their sensitivities are 
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not equivalent. OCT3 and PMAT are the most sensitive to decynium-22 
inhibition (IC50 = 9-100 nM for OCT3, 100 nM for PMAT), while OCT1 is 
significantly less sensitive (IC50 = 0.5-1μM) [13, 23, 42-44]. Some 
reports have suggested that, at very high concentrations, decynium-
22 can inhibit NET and SERT [45, 46]. In the present studies, 
decynium-22 inhibited approximately 80% of [3H]-MPP+ accumulation 
with the same potency (IC50 = 3.4 nM) as reported in our previous 
studies [29]. As the concentrations of decynium-22 used in the current 
study (0.01 nM – 0.1 μM) did not reach the previously reported IC50s 
for OCT1, the data suggest that the decynium-22-sensitive fraction of 
MPP+ accumulation reported here is mediated primarily by PMAT and 
OCT3, and that the remaining fraction of MPP+ accumulation is 
mediated by OCT1, with a possible contribution of SERT. 
 
 While all of the uptake2 transporters expressed in CGNs are 
inhibited by corticosterone, they differ greatly in their sensitivity. OCT3 
is the most corticosterone-sensitive, followed by OCT1 and PMAT [3, 
13, 16-18, 47]. The concentrations of corticosterone used in the 
current study did not reach the previously-reported IC50s for inhibition 
of OCT1 (150 μM) or PMAT (450 μM). Thus, the corticosterone-
sensitive MPP+ uptake (50-60% of total uptake) observed in the 
present study is likely mediated primarily by OCT3, with the 
corticosterone-insensitive fraction (40-50% of total uptake) mediated 
by PMAT and OCT1. Given the high levels of PMAT mRNA we detected 
in relation to OCT3, it is surprising that the corticosterone-insensitive 
fraction of MPP+ accumulation in CGNs is not larger. This may be due 
to differences in the efficiencies with which OCT3 and PMAT transport 
MPP+. In support, recently published studies demonstrated that the 
Vmax for OCT3-mediated MPP+ uptake is twofold higher than that of 
PMAT [18]. 
 
Previous studies demonstrated that corticosterone-induced 
inhibition of OCT3-mediated transport is a non-genomic, GR-
independent phenomenon [7]. The present studies are consistent with 
a non-genomic mechanism, in that inhibition of MPP+ uptake by all 
tested corticosteroids was evident with only 5 minutes of steroid 
exposure, and that the GR antagonist RU38486 also inhibited MPP+ 
accumulation. The IC50 for corticosterone inhibition of MPP+ 
accumulation reported in the present study (81 nM) is consistent with 
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previous studies [3, 29], and is within the physiological range reported 
for stress-induced corticosterone concentrations the rat brain [48, 49]. 
 
While each of the individual uptake2 transporters is inhibited by 
corticosterone, their sensitivities to other corticosteroids have not been 
thoroughly characterized. Early studies in peripheral tissues 
demonstrated that a variety of natural corticosteroids inhibit uptake2 
activity or enhance the actions of epinephrine [11, 12]. However, the 
effects of corticosteroids other than corticosterone on individual 
uptake2 transporters have been examined only for OCT3. Those 
studies demonstrated that OCT3 is inhibited by budesonide, 
methylprednisolone, and fluticasone [7, 28]. Our data indicate that 
uptake2-mediated transport in the CNS is broadly sensitive to inhibition 
by natural and synthetic corticosteroids. While it is likely that these 
corticosteroids exert their effects at least in part by inhibiting OCT3, 
further studies are required to determine the specific contributions of 
each of the expressed transporters to corticosteroid-sensitive uptake. 
 
The mineralocorticoids aldosterone and 11-DOC also inhibited 
MPP+ accumulation by CGNs. This is consistent with previous studies, 
which demonstrated that these two mineralocorticoids could inhibit the 
clearance of epinephrine and norepinephrine, and potentiate their 
actions in vascular or cardiac tissue [11, 12, 50, 51]. This is the first 
study demonstrating mineralocorticoid-sensitive transport in CNS cells, 
and suggests that mineralocorticoids also exert actions in the CNS by 
inhibiting uptake2-mediated monoamine clearance. Interestingly, OCT3 
knockout mice display alterations in salt intake that are comparable to 
those exhibited by aldosterone-treated animals [15]. As OCT3 protein 
and mRNA are expressed in brain regions involved in regulation of salt 
intake, including circumventricular organs and medial amygdala, these 
data raise the possibility that this particular uptake2 transporter 
represents a target for mineralocorticoid action on ingestive behavior 
[4, 15]. 
 
Comparison of the effects of corticosterone, 11-DOC and 11-
dehydrocorticosterone on MPP+ accumulation indicates that slight 
differences in corticosteroid structure significantly alter potency and 
efficacy of steroid-mediated inhibition of uptake2. These three steroids 
differ in structure only at C11 of the steroid backbone. 11-
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Deoxycorticosterone, which differs from corticosterone only by the lack 
of a hydroxyl group at C11, was a more potent and slightly more 
effective inhibitor of MPP+ accumulation than was corticosterone, 
suggesting that the lack of the C11 hydroxyl group may increase the 
potency of 11-DOC at OCT3 and/or make it a more effective inhibitor 
of PMAT and/or OCT1. 11-Dehydrocorticosterone, which contains a 
keto- group at C11, was a much less effective inhibitor than either 
corticosterone or 11-DOC. Further studies are necessary to determine 
the effects of these steroids on individual uptake2 transporters. 
 
The present studies are the first to demonstrate sensitivity of 
uptake2 activity to dexamethasone, prednisolone, and betamethasone, 
and to demonstrate that uptake2-mediated transport in the CNS is 
sensitive to synthetic corticosteroids. These results are consistent with 
studies demonstrating that OCT3-mediated monoamine transport in 
bronchial smooth muscle cells is inhibited by budesonide, fluticasone 
and methylprednisolone [7, 28]. Again, further studies are required to 
determine the relative contributions of OCT3, OCT1 and PMAT to the 
effects of each of the tested synthetic steroids. However, these studies 
raise the interesting possibility that synthetic corticosteroids may 
acutely and potently enhance monoaminergic neurotransmission in the 
CNS, and that these actions may in part underlie previously described 
acute effects of synthetic corticosteroid treatment on behavior in 
humans [52-54]. 
 
Both natural and synthetic corticosteroids have powerful effects 
on monoamine-regulated behaviors, [52-59, 59]. Accumulating 
evidence suggests that uptake2 transporters may play important roles 
in regulating monoaminergic neurotransmission in specific brain 
regions [1, 3, 24, 25]. The present studies demonstrate that uptake2 
represents an important target for corticosteroid action in the brain 
and that inhibition of uptake2-mediated clearance of monoamines must 
be taken into consideration when interpreting the results of acute 
treatment with both natural and synthetic corticosteroid hormones. 
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Figure 1. Expression of monoamine transporters in CGNs. RT-PCR was performed 
using total RNA extracted from CGNs and primers specific to OCTs 1, 2, and 3, plasma 
membrane monoamine transporter (PMAT), dopamine (DAT), norepinephrine (NET) or 
serotonin reuptake transporter (SERT). PCR was performed on cDNA samples 
generated in the presence (+) or absence (-) of reverse transcriptase. Only RT-PCR 
that included reverse transcriptase (+) produced distinct bands for any of the 
transporters. mRNAs for OCT1, OCT3 and PMAT were clearly detected, and a very 
small amount of mRNA for SERT was detected, in CGNs. 
 
 
Figure 2. Effects of Decynium-22 and corticosterone on CGN accumulation of [3H]-
MPP+. Cultured CGNs were incubated in uptake buffer containing the indicated 
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concentrations of inhibitors for 5 min, after which 20 nM [3H]-MPP+ was added and 
uptake was measured after 2 min. Decynium-22 (Δ) and corticosterone (●) inhibited 
[3H]-MPP+ accumulation in a concentration-dependent manner. Error bars represent − 
SE from n = 3 (decynium-22) or 8 (corticosterone) replicate wells. 
 
 
Figure 3. Effects of corticosteroids on CGN accumulation of [3H]-MPP+. Cultured 
CGNs were incubated in uptake buffer containing the indicated concentrations of 
inhibitors for 5 min, after which 20 nM [3H]-MPP+ was added and uptake was 
measured after 2 min. Aldosterone (о), cortisol (●) and cortisone (Δ) inhibited [3H]-
MPP+ accumulation in a concentration-dependent manner. Error bars represent − SE 
from n = 3 (aldosterone, cortisone) or 4 (cortisol) replicate wells. 
 
 
Figure 4. Effects of corticosterone and its metabolites on accumulation of [3H]-
MPP+ by CGNs. Cultured CGNs were incubated in uptake buffer containing the 
indicated concentrations of steroids for 5 min, after which 20 nM [3H]-MPP+ was added 
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and uptake was measured after 2 min. The data for corticosterone (●) are from Figure 
2, presented here for comparison to the other steroids. Both 11-deoxycorticosterone 
(о) and 11-dehydrocorticosterone (Δ) inhibited [3H]-MPP+ accumulation in a 
concentration-dependent manner, though with different efficacies. Error bars 
represent − SE from n = 3 (11-dehydrocorticosterone, 11-deoxycorticosterone) or 8 
(corticosterone) independent wells. 
 
 
Figure 5. Effects of synthetic corticosteroids on accumulation of [3H]-MPP+ by 
CGNs. Cultured CGNs were incubated in uptake buffer containing the indicated 
concentrations of steroids for 5 min, after which 20 nM [3H]-MPP+ was added and 
uptake was measured after 2 min. A. Betamethasone (), prednisolone (●) and 
RU38486 (о) dose-dependently inhibited [3H]-MPP+ accumulation. B. Dexamethasone 
(●) dosedependently inhibited [3H]-MPP+ accumulation. Error bars represent − SE 
from n = 3 (betamethasone, prednisolone, RU38486) wells or − SD from two 
(dexamethasone) wells. 
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